Smoldering myeloma
Showing 1 - 25 of 2,474
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Ciltacabtagene Autoleucel
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 2, 2023
Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)
Not yet recruiting
- Multiple Myeloma
- Teclistamab
- +2 more
-
Miami, FloridaUniversity of Miami
Oct 20, 2023
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,
Recruiting
- High-risk Smoldering Multiple Myeloma
- +2 more
- Teclistamab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Aug 11, 2022
Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM) Trial in Rochester (Curcumin plus Piperine)
Recruiting
- Prostate Cancer
- +3 more
- Curcumin plus Piperine
-
Rochester, New YorkUniversity of Rochester
Jun 17, 2022
Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)
Not yet recruiting
- Smoldering Multiple Myeloma (SMM)
- (no location specified)
Jul 13, 2023
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)
Not yet recruiting
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Smoldering Multiple Myeloma (SMM)
- (no location specified)
Nov 17, 2023
Smoldering Multiple Myeloma Trial in Rochester (Denosumab)
Active, not recruiting
- Smoldering Multiple Myeloma
-
Rochester, New YorkUniversity of Rochester
Oct 3, 2022
Monoclonal Gammopathy, Smoldering Myeloma, Myeloma Trial in Cleveland (DKK1)
Not yet recruiting
- Monoclonal Gammopathy
- +2 more
- DKK1
-
Cleveland, Ohio
- +1 more
Nov 29, 2021
Smoldering Multiple Myeloma Trial in Boston (Nivolumab, Lenalidomide, Dexamethasone)
Suspended
- Smoldering Multiple Myeloma
- Nivolumab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 4, 2022
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Oslo (TG01)
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- TG01
-
Oslo, NorwayOslo Myeloma Center
May 2, 2023
Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)
Recruiting
- Multiple Myeloma
- Dexamethasone
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- High Risk Smoldering Multiple Myeloma
- Ixazomib (MLN9708)
- Dexamethasone
-
Basking Ridge, New Jersey
- +5 more
Nov 15, 2022
Smoldering Myeloma, Smoldering Multiple Myeloma Trial in United States (Elotuzumab, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Myeloma
- Smoldering Multiple Myeloma
- Elotuzumab
- +2 more
-
Denver, Colorado
- +8 more
Nov 1, 2021
Multiple Myeloma, Smoldering Trial in United States (Omega-3, Curcumin, Probiotic)
Recruiting
- Multiple Myeloma, Smoldering
- Omega-3
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 1, 2023
High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- High-risk Smoldering Multiple Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 18, 2021
Quality of Life in Asymptomatic Monoclonal Gammopathies
Recruiting
- Monoclonal Gammopathy of Undetermined Significance
- Smoldering Plasma Cell Myeloma
- Quality-of-Life Assessment
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Smoldering Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Daratumumab)
Active, not recruiting
- Smoldering Multiple Myeloma
- Carfilzomib
- +3 more
-
Tampa, Florida
- +9 more
Jul 8, 2022
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in Cleveland (Multiple
Not yet recruiting
- Multiple Myeloma
- +2 more
- Multiple Myeloma M-Protein Analysis
- Multiple Myeloma Knowledge Questionnaires
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Apr 26, 2023
Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 15, 2022
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma Trial in United States (Metformin XR, Placebo)
Recruiting
- Monoclonal Gammopathy of Undetermined Significance
- Smoldering Multiple Myeloma
- Metformin XR
- Placebo
-
Boston, Massachusetts
- +6 more
Oct 3, 2022
Myeloma Trial in Houston (Belantamab mafodotin)
Recruiting
- Myeloma
- Belantamab mafodotin
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Smoldering Plasma Cell Myeloma Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)
Active, not recruiting
- Smoldering Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 23, 2022
Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM) Trial in Boston (Prolonged Fasting Intervention,
Not yet recruiting
- Cancer Prevention
- +5 more
- Prolonged Fasting Intervention
- EDUCATION CONTROL
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 28, 2022
Two Biologically and Clinically Distinct Entities: Progressive
Recruiting
- Multiple Myeloma
- +2 more
-
Miami, FloridaUniversity of Miami Hospitals
Jun 7, 2022